Skip to content
Sign in

SBIO · ARCA · ETF

ALPS Medical Breakthroughs ETF (SBIO) Price, Holdings & Fees

$752.67+0.50%+$3.78End-of-day price as of Oct 9, 2026

ALPS Medical Breakthroughs ETF (SBIO) closed at $752.67 on Oct 9, 2026, up 0.50% from the previous close of $748.89.

Share price, past year

1Y +22.32%

52-week range $600.82 – $767.10. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$752.67
Sep 30, 2026$738.66
Aug 31, 2026$739.57
Jul 31, 2026$743.91
Jun 30, 2026$725.16
May 29, 2026$668.34
Apr 30, 2026$692.61
Mar 31, 2026$713.55
Feb 27, 2026$687.82
Jan 30, 2026$669.98
Dec 31, 2025$701.49
Nov 28, 2025$652.08
Oct 31, 2025$617.12

Key statistics

Expense ratio
0.50%
as of Mar 31, 2026
Net assets
$161.8M
as of May 31, 2026
Holdings
89
as of May 31, 2026
52-week range
$600.82 – $767.10

ALPS Medical Breakthroughs ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

Holdings

ALPS Medical Breakthroughs ETF held 89 investments worth $161.79M as of May 31, 2026. Its largest holding was Alkermes Plc, at 4.48% of the fund.

ALPS Medical Breakthroughs ETF largest holdings by share of net assets
#Holding% of fundValue
1Alkermes Plc4.48%$7.24M
2Kymera Therapeutics Inc4.23%$6.85M
3Celcuity Inc3.92%$6.34M
4Mirum Pharmaceuticals Inc3.90%$6.31M
5Spyre Therapeutics Inc3.68%$5.95M
6Cg Oncology Inc3.35%$5.42M
7Apogee Therapeutics Inc2.93%$4.74M
8Xenon Pharmaceuticals Inc2.90%$4.69M
9Travere Therapeutics Inc2.77%$4.48M
10Dianthus Therapeutics Inc2.64%$4.26M
11Newamsterdam Pharma Co Nv2.47%$3.99M
12Viking Therapeutics Inc2.41%$3.90M
13Crinetics Pharmaceuticals Inc2.37%$3.84M
14Acadia Pharmaceuticals Inc2.35%$3.81M
15Edgewise Therapeutics Inc2.33%$3.78M
16Denali Therapeutics Inc2.13%$3.44M
17Oruka Therapeutics Inc1.81%$2.92M
18Structure Therapeutics Inc1.78%$2.87M
19Disc Medicine Inc1.69%$2.74M
20Ideaya Biosciences Inc1.65%$2.67M
21Vera Therapeutics Inc1.61%$2.61M
22Tarsus Pharmaceuticals Inc1.61%$2.61M
23Relay Therapeutics Inc1.60%$2.59M
24Mineralys Therapeutics Inc1.59%$2.57M
25Celldex Therapeutics Inc1.33%$2.16M

Top 25 of 89 holdings, as of May 31, 2026. Percentages are of the fund's net assets.

What the fund owns

ALPS Medical Breakthroughs ETF holdings by asset type
Asset type% of fund
Stocks100.03%
ALPS Medical Breakthroughs ETF holdings by country, largest 8
Country% of fund
United States80.20%
Netherlands4.68%
Cayman Islands4.66%
Ireland4.48%
Canada2.90%
Belgium1.19%
United Kingdom1.08%
Switzerland0.84%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to May 31, 2026, ALPS Medical Breakthroughs ETF's total return was +5.39%, as reported to the SEC.

ALPS Medical Breakthroughs ETF monthly total returns
MonthTotal return
May 31, 2026+1.42%
Apr 30, 2026+2.58%
Mar 31, 2026+1.30%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
ALPS Medical Breakthroughs ETF
Ticker
SBIO
Exchange
ARCA
Fund type
ETF
Trust
ALPS ETF Trust
SEC series ID
S000047823
SEC CIK
0001414040
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by ALPS ETF Trust, the trust behind ALPS Medical Breakthroughs ETF, and cover all of its funds.

Frequently asked questions

What is SBIO's price?

ALPS Medical Breakthroughs ETF (SBIO) closed at $752.67 on Oct 9, 2026, up 0.50% from the previous close of $748.89.

What is SBIO's expense ratio?

ALPS Medical Breakthroughs ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

What does SBIO hold?

ALPS Medical Breakthroughs ETF held 89 investments worth $161.79M as of May 31, 2026. Its largest holding was Alkermes Plc, at 4.48% of the fund. Its five largest holdings were Alkermes Plc, Kymera Therapeutics Inc, Celcuity Inc, Mirum Pharmaceuticals Inc, Spyre Therapeutics Inc.

How has SBIO performed?

Over the 3 months to May 31, 2026, ALPS Medical Breakthroughs ETF's total return was +5.39%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 29, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Mar 31, 2026. Prices are generated sample data for development. Data sources and disclosures